|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.19 USD | +0.81% |
|
+3.19% | -9.81% |
REGENXBIO Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 22.21 million compared to USD 31.35 million a year ago. Net loss was USD 62.89 million compared to USD 59.94 million a year ago.
Basic loss per share from continuing operations was USD 1.43 compared to USD 1.38 a year ago. Diluted loss per share from continuing operations was USD 1.43 compared to USD 1.38 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -9.81% | 794M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
REGENXBIO INC. 
